Advertisement Banner
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
No Result
View All Result
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact
No Result
View All Result
HealthNews
No Result
View All Result
Home Health Tech News

Axicabtagene ciloleucel significantly extends survival in large B-cell lymphoma

admin by admin
March 22, 2023
in News


March 21, 2023

1 min read




ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Axicabtagene ciloleucel significantly extended survival compared with historic standard of care in a curative setting for adults with previously untreated relapsed or refractory large B-cell lymphoma, according to the agent’s manufacturer.

Results of the randomized phase 3 ZUMA-7 study showed the improvement in OS, a prespecified key secondary endpoint, among patients who were refractory to first-line chemoimmunotherapy or experienced disease relapse within 12 months of initial treatment.

CAR T-cell therapy, 3d rendering
As initial treatment for adults with relapsed/refractory large B-cell lymphoma, axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences) demonstrated a statistically significant improvement in survival vs. historic treatment, according to a Kite Pharma press release. Image: Adobe Stock

Axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences) — also known as axi-cel — is an autologous, gene-edited, CD19-directed chimeric antigen receptor T-cell therapy. FDA approved axi-cel last year as initial treatment of relapsed/refractory large B-cell lymphoma based on data from the ZUMA-7 trial.

ZUMA-7 examined the safety and efficacy of axi-cel vs. standard of care among 359 adults with relapsed or refractory large B-cell lymphoma at 77 centers worldwide. Standard of care consists of a platinum-based salvage combination chemoimmunotherapy regimen followed by high-dose therapy and autologous hematopoietic stem cell transplantation for responders to the chemoimmunotherapy.

EFS served as the primary endpoint.

Results showed a 2.5-fold increase compared with standard of care in the percentage of patients alive at 2 years who did not experience disease progression or require additional cancer treatment (40.5% vs. 16.3%). Researchers reported a fourfold increase in median EFS (8.3 months vs. 2 months; HR = 0.39; 95% CI, 0.3-0.51) with axi-cel vs. standard of care, as well as higher rates of overall response (83% vs. 50%; OR = 5.31; 95% CI, 3.1-8.9) and complete response (65% vs. 32%).

An interim OS analysis occurred at the time of the primary EFS analysis, with the prespecified primary OS analysis to be conducted after 210 deaths or no later than 5 years after random assignment of the first patient in the trial, according to a Kite press release.

Axi-cel had a safety profile consistent with that of prior studies. Grade 3 or higher cytokine release syndrome occurred among 7% and neurologic events among 25% of the 168 safety-evaluable patients who received axi-cel. Most patients in the standard-of-care group (83%) experienced high-grade events, mostly cytopenias.

Complete results will be presented at a medical meeting later this year, according to the press release.




ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.


Immuno-Oncology Resource Center



Source link

Advertisement Banner
Previous Post

Expectations May Influence Post-Knee Replacement Experiences

Next Post

After Breast Cancer: Fitness and Nutrition Tips

Next Post

After Breast Cancer: Fitness and Nutrition Tips

Discussion about this post

Recommended

Dr Mansukh Mandaviya, Health News, ET HealthWorld

2 months ago

Adcetris Approved for Pediatric Patients With High-Risk Classical Hodgkin Lymphoma

7 months ago

Don't Miss

The Uncommon Heart Attack That Kills Healthy, Young Women

May 30, 2023

Technology can help make healthcare far more accessible, Health News, ET HealthWorld

May 30, 2023

Scientists Narrow Down Long COVID Symptoms To 12 From 200 Reported Health Problems

May 30, 2023

Build a Care Team You Trust

May 30, 2023

© Pharma News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Medicine
  • Health Tech
  • Health Tech
  • Health Living
  • Contact
  • Privacy Policy

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Medicine
  • Health Tech
  • Health Living
  • Contact

© 2022 Pharma News Hubb All rights reserved.